{
    "clinical_study": {
        "@rank": "114270", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Experimental", 
                "description": "Infusion of one MPC expanded cord unit and one unexpanded cord unit."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Active Comparator", 
                "description": "Infusion of two unexpanded cord blood units."
            }
        ], 
        "brief_summary": {
            "textblock": "The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in\n      patients with hematologic malignancies undergoing transplantation with myeloablative\n      conditioning."
        }, 
        "brief_title": "P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Acute Lymphoblastic Leukemia", 
            "Non-Hodgkin's Lymphoma", 
            "Hodgkin's Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have one of the following:\n\n               -  Acute myelogenous leukemia (AML) in complete morphological remission at study\n                  screening (Complete Remission with Incomplete Platelet Recovery  (CRp)\n                  acceptable).\n\n               -  Acute lymphoblastic leukemia (ALL) in complete morphological remission at study\n                  screening (Complete Remission with Incomplete Platelet Recovery  (CRp)\n                  acceptable).\n\n               -  Non-Hodgkin's lymphoma (NHL): High risk subjects with responsive disease after\n                  first relapse.  High risk includes those with Burkitt's Lymphoma and those with\n                  extensive marrow involvement at diagnosis-precluding autologous transplant.\n\n               -  Hodgkin's disease: High risk subjects with responsive disease after first\n                  relapse.\n\n          -  Minimum Karnofsky Scale\n\n          -  Subject must weigh at least 20 kg\n\n          -  Up to 65 years of age\n\n          -  Adequate major organ system function\n\n        Exclusion Criteria:\n\n          -  Pregnancy and/or lactating\n\n          -  Suitable, 6/6 HLA matched related sibling donor available\n\n          -  Previous participation in a stem cell study within last 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854567", 
            "org_study_id": "CB-AB006", 
            "secondary_id": "2012-0166"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "description": "Infusion of one MPC expanded cord unit and one unexpanded cord unit.", 
                "intervention_name": "Infusion of one MPC expanded cord unit and one unexpanded cord unit", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Umbilical Cord Blood.", 
                "intervention_name": "Infusion of two unexpanded cord blood units.", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cord Blood", 
            "Stem Cells", 
            "MPC", 
            "Mesoblast", 
            "Expanded", 
            "AML", 
            "ALL", 
            "NHL", 
            "Leukemia", 
            "Lymphoma"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Moffitt Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Marcie Tomblyn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weill Cornell-New York Presbyterian Hospital"
                }, 
                "investigator": {
                    "last_name": "Tsiporah B Shore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Juliette Barker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valhalla", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10595"
                    }, 
                    "name": "Westchester Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mitchell Cairo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western"
                }, 
                "investigator": [
                    {
                        "last_name": "Hillard Lazarus, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marcos deLima, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Elizabeth J Shpall, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Texas Transplant Center at Methodist Healthcare System"
                }, 
                "investigator": {
                    "last_name": "Paul Shaughnessy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment", 
        "other_outcome": {
            "measure": "Incidence and severity of acute Graft Versus Host Disease", 
            "safety_issue": "Yes", 
            "time_frame": "100 days"
        }, 
        "overall_contact": {
            "email": "rebecca.cohen@mesoblast.com", 
            "last_name": "Rebecca Cohen"
        }, 
        "overall_official": [
            {
                "affiliation": "Mesoblast, Ltd.", 
                "last_name": "Donna Skerrett, MD, MS", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "M.D. Anderson Cancer Center", 
                "last_name": "Elizabeth J. Shpall, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to Neutrophil and Platelet Engraftment", 
            "safety_issue": "No", 
            "time_frame": "100 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854567"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with neutrophil recovery at day 26, platelet recovery at day 60  and subjects alive at day 100", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "measure": "Percentage of patients with primary graft failure", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }
        ], 
        "source": "Mesoblast, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mesoblast, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}